We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Merck & Co., Inc. (NYSE:MRK) is one of ...

Merck trades at a low P/E with strong financials, Keytruda growth, and a solid 3.9% yield, while its pipeline offsets future risks. Read why MRK stock is a buy.

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck’s second quarter performance aligned with Wall Street’s revenue expectations but drew a negative reaction from the ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Meanwhile, mRNA vaccine maker Moderna is cutting around 500 jobs (10% of its workforce) as part of a commitment to save $1.5 ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Regardless of whether Merck gains approval for clesrovimab, Sanofi still sees Beyfortus continuing its growth in 2025, according to chief financial officer François Roger during the company’s ...

Merck has been named a Fortune 500 company in 2022 with awards for innovation, including CPhI Awards, R&D Magazine 100 awards, and the 2019 Innovation SABRE Award.